Albany, New York, September 25, 2017: The global subcutaneous immunoglobulin market is projected to grow at double-digit CAGR through 2024. Demand for subcutaneous immunoglobulin products is influenced by increasing focus on treating primary immunodeficiency diseases. The healthcare infrastructure in many emerging countries has gained center stage owing to concerted efforts on part of governments. On account of these factors, the global subcutaneous immunoglobulin market is expected to reach nearly US$ 9 bn by 2024. These insights are according to a new research report, “Subcutaneous Immunoglobulin Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024” added to the database of Market Research Reports Search Engine (MRRSE) offers key insights and analysis shaping the global subcutaneous immunoglobulin market globally.
The global subcutaneous immunoglobulin market has been positively impacted by advancements in drug development. A number of therapeutically advanced drugs have been launched in the market that aim to reduce adverse impacts, while reducing the infusion times. Demand for managing PIDD is also fuelling the demand for subcutaneous immunoglobulin drugs.
To offer readers a comprehensive outlook on the global subcutaneous immunoglobulin market, the report segments the global market on the basis of end-users and application. The key application areas of subcutaneous immunoglobulin include primary immunodeficiency diseases and secondary immunodeficiency diseases – of these, the former accounts for the leading market share. According to the report, primary immunodeficiency disease segment accounts for nearly 70% revenue share, and its dominance is expected to continue during the forecast period. Innovation in plasma derived therapeutics remains a key factor for the growth of this segment.
On the basis of end-users, the key segments include hospitals, clinics, and home care. Among these, demand for subcutaneous immunoglobulin drugs is highest in home care settings. According to the report, home care segment was valued at nearly US$ 2 bn in 2016; during the forecast period, this segment will remain the most lucrative in terms of end users.
Infusion of immunoglobulin through subcutaneous route is being preferred over intravenous route, as the former can be self-administered after providing training to the patient.
Region-wise, North America is the largest market for subcutaneous immunoglobulin. The North America subcutaneous immunoglobulin market is projected to surpass US$ 3.5 bn by 2024. In addition to North America, the demand from emerging countries of APEJ is also likely to provide an impetus to the growth of the market. Many countries in APEJ are moving towards a complete overhaul of their healthcare services, providing an impetus to diagnostic and treatment sectors. It is expected that APEJ will provide growth opportunities to manufacturers during the forecast period.
The key players operating in the global subcutaneous immunoglobulin market include CSL Behring LLC, Biotest AG, Baxalta Incorporated Grifols S.A., Shire Plc., Kedrion S.p.A., Octapharma AG, , and Talecris Biotherapeutics, Inc
Browse Full Global Subcutaneous Immunoglobulin Market Report with TOC : http://www.mrrse.com/subcutaneous-immunoglobulin-market
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
90, State Street
Albany, NY – 12207